Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma

Siesing, Christina; Svensson, Marcus; Hedner, Charlotta; Nodin, Björn; Borg, David; Jirström, Karin

doi:10.1093/annonc/mdy282.039

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several biomarkers have been associated with the outcomes of NCRT-treated LAGC, including overexpressed ERCC1 and ERCC2 [ 4 ], LAG-3 [ 85 ], microRNAs (miRs) 338-3p and miR-142-3p [ 86 ], T-cell density, and 5-fluorouracil-related enzymes [ 87 , 88 ]. Before these biomarkers are applied to clinical practice, further validation of these findings is required.…”

Section: Toxicity Therapeutical Considerations and Biomarkers Of Ncrtmentioning

confidence: 99%

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Yeh

Tsai

et al. 2022

Cancers

View full text Add to dashboard Cite

Locally advanced gastric cancer (LAGC) has a poor prognosis with surgical resection alone, and neoadjuvant treatment has been recommended to improve surgical and oncological outcomes. Although neoadjuvant chemotherapy has been established to be effective for LAGC, the role of neoadjuvant chemoradiotherapy (NCRT) remains under investigation. Clinical experience and research evidence on esophagogastric junction adenocarcinoma (e.g., cardia gastric cancers) indicate that the likelihood of achieving sustainable local control is higher through NCRT than through resection alone. Furthermore, NCRT also has an acceptable treatment-related toxicity and adverse event profile. In particular, it increases the likelihood of achieving an R0 resection and a pathological complete response (pCR). Moreover, NCRT results in higher overall and recurrence-free survival rates than surgery alone; however, evidence on the survival benefits of NCRT versus neoadjuvant chemotherapy (NCT) remains conflicting. For noncardia gastric cancer, the efficacy of NCRT has mostly been reported in retrospective studies, and several large clinical trials are ongoing. Consequently, NCRT might play a more essential role in unresectable LAGC, for which NCT alone may not be adequate to attain disease control. The continual improvements in systemic treatments, radiotherapy techniques, and emerging biomarkers can also lead to improved personalized therapy for NCRT. To elucidate the contributions of NCRT to gastric cancer treatment in the future, the efficacy, potential toxicity, predictive biomarkers, and clinical considerations for implementing NCRT in different types of LAGC were reviewed.

show abstract

Section: Toxicity Therapeutical Considerations and Biomarkers Of Ncrtmentioning

confidence: 99%

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Yeh

Tsai

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…It is expressed on activated T-cells, Tregs, NK-cells, B-cells and plasmacytoid DCs, and plays an important role in negative regulation of T-cell proliferation via binding to MHC class II with high affinity [120]. LAG-3 expression has been shown in approximately 50% of treatment naïve primary GOAs and lymph node metastases [121], with expression increasing over four-fold post-NAT in OAC patients [111], and is significantly correlated with PD-L1 expression on both tumour cells and TILs in OAC [111,121]. LAG-3 has also been shown to be an independent factor for increased survival in GOCs [121].…”

Section: Immune Checkpoint Moleculesmentioning

confidence: 99%

“…LAG-3 expression has been shown in approximately 50% of treatment naïve primary GOAs and lymph node metastases [121], with expression increasing over four-fold post-NAT in OAC patients [111], and is significantly correlated with PD-L1 expression on both tumour cells and TILs in OAC [111,121]. LAG-3 has also been shown to be an independent factor for increased survival in GOCs [121]. Co-expression of LAG-3 with PD-1 has been shown to mark dysfunctional or exhausted CD8 + T-cells; and in pre-clinical models, LAG-3 and PD-1 co-blockade improved the proliferation and cytokine production of tumour-antigen-specific CD8 + T-cells [122,123].…”

Section: Immune Checkpoint Moleculesmentioning

confidence: 99%

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches

Lonie

Barbour

Dolcetti

2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

With an incidence that is constantly rising, oesophageal adenocarcinoma (OAC) is becoming an increasing health burden worldwide. Although significant advances in treatment regimens have improved patient outcomes, survival rates for this deadly cancer remain unsatisfactory. This highlights the need to improve current therapeutic approaches and develop novel therapeutic strategies for treating OAC patients. The advent of immunotherapy has revolutionised treatment across a range of malignancies, however outcomes in OAC show modest results. The inherent resistance of OAC to treatment reflects the complex genomic landscape of this cancer, which displays a lack of ubiquitous driver mutations and large-scale genomic alterations along with high tumour and immune heterogeneity. Research into the immune landscape of OAC is limited, and elucidation of the mechanisms surrounding the immune responses to this complex cancer will result in improved therapeutic approaches. This review explores what is known about the immuno-biology of OAC and explores promising therapeutic avenues that may improve responses to immunotherapeutic regimens.

show abstract

Lymphocyte activation gene-3 as a candidate target for combo anti-programmed death-(ligand) 1 therapy of cancer

Mortezaee

2024

Process Biochemistry

View full text Add to dashboard Cite

Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma

Cited by 5 publications

References 0 publications

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches

Lymphocyte activation gene-3 as a candidate target for combo anti-programmed death-(ligand) 1 therapy of cancer

Contact Info

Product

Resources

About